

**Избрани публикации по конкурса за член кореспондент
(общ IF = 174.828)**

2005

1. **Petrova G.**, Benisheva T. Pharmacoeconomics and the new Bulgarian positive list. Regulatory Affair Journal, 2005; 175-178

2007

2. Bogavac-Stanojevic N., **Petrova G.**, Jelic Z., Memon L., Spasic S. Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. Clinical Biochemistry 2007; 40: 1180-1187
IF=2.8

2008

3. Stevanovic PD, **Petrova G.**, Miljkovic B, Scepanovic R, Perunovic R, Stojanovic D, Dobrasinovic J. Low fresh gas flow balanced anesthesia versus target controlled intravenous infusion anesthesia in laparoscopic cholecystectomy: a cost-minimization analysis. Clin Ther. 2008; 30(9):1714-25. doi: 10.1016/j.clinthera.2008.09.009.
IF=3.2
4. Clerfeuille F., Poubanne Y., Vakrilova M., **Petrova G.** Evaluation of consumer satisfaction using the tetra-class model. Research in Social and Administrative Pharmacy 2008; 4: 258–271
IF=3.9

2009

5. **Petrova G.**, A. Stoimenova, M. Manova. Cost-effectiveness of peginterferon alfa2B. in HCV infection: A Bulgarian scenario. Archives of Balkan Medical Union 2009; 44 (3) : 215-219
6. Ivanova A., **Petrova G.** Hypertension and common complications – analysis of the ambulatory therapy treatment cost. Cent Eur J Public Health 2009; 17 (4): 223–230
IF=1.2
7. **Petrova G.**, Clerfeuille F, Vakrilova M, Mitkov C, Poubanne Y. The applicability of the tetra-class model to the management of the patient satisfaction in the pharmacies. Pharmacy Practice (Internet) 2009;7(1):19-28.

2010

8. Manoela Manova, Assena Stoimenova, Fabrice Clerfeuille, **Guenka Petrova**. Impact of the generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market. Journal of Public Health, 2010; 19 (1): 91-100.
IF=1.8

2011

9. Desancic, S., Stoimenova, A., Savova, A., Manova, M., Petkova, V., **Petrova, G.** Pharmacoeconomics of rare diseases therapy - An example of phenylketonuria. Acta Medica Bulgarica, 2011; 38 (1): 84-89.
10. Manova, M., Peikova, L., Peikov, P., **Petrova G.** Patent protection policy in the therapeutic group of statins. Biotechnology and Biotechnological Equipment, 2011; 25 (4): 2683-2687. DOI: 10.5504/BBEQ.2011.0066
IF=0.622

11. Manova, M., Stoimenova, A., Savova, A., Peikov, P., **Petrova, G.** Utilization and price trends in some reimbursed cardiovascular medicines. *Biotechnology and Biotechnological Equipment*, 2011; 25&2424-2432. DOI: 10.5504/bbeq.2011.0033
IF=0.622
12. Stoimenova, A., Manova, M., Savova, A., Angelovska, B., **Petrova, G.** Reimbursed orphan medicines in Bulgaria and the share of biotechnology-derived products. *Biotechnology and Biotechnological Equipment*, 2011; 25 (2): 2418-2423. DOI: 10.5504/bbeq.2011.0043
F=0.622
13. Ivanova, A., **Petrova, G.**, Wrona, W., Valov, V., Stoimenova, A., Czech, M. Modelling the long-term effect of diabetes therapy. An example with liraglutide. *Comptes Rendus de L'Academie Bulgare des Sciences*, 2011; 64 (3): 449-456.
IF=0.223
14. Dimitrova, M., **Petrova G.** Pharmacoeconomic studies of the highly active antiretrovirus therapy of HIV/AIDS. *Pharmacia*, 2011; 59 (1-4): 72-84.
15. **Petrova, G.**, Ivanova, A., Czech, M., Valov, V., Wrona, W., Niewada, M., Savova, A. Liraglutide vs. exenatide in combination with metformin and/or sulfonylurea therapy in type 2 diabetes mellitus therapy in Bulgaria: A modelling study. *Comptes Rendus de L'Academie Bulgare des Sciences*, 2011; 64 (10): 1507-1514.
IF=0.223
16. Dimitrova, M., **Petrova G.**, Cervenjakova, T., Jancheva, N., Stefanova, M., Manova, M., Savova, A., Stoimenova, A. Budget impact model of new antiretroviral biotechnology medicines for treatment of HIV/AIDS patients in Bulgaria. *Biotechnology and Biotechnological Equipment*, 2011; 25 (3):2547-2554. DOI: 10.5504/bbeq.2011.0053
IF=0.622
17. Lakic, D., **Petrova G.**, Bogavac-Stanojević, N., Jelić-Ivanović, Z. Impact of discounting in pharmacoeconomic modeling. A case study. *Biotechnology and Biotechnological Equipment*, 2011; 25 (3): 2555-2558. DOI: 10.5504/bbeq.2011.0065
IF=0.622

2012

18. Jasmina, T., Genchev, G., Savova, A., Dantchev, N., **Petrova, G.** Cost-effectiveness and activities of daily living in patients with complex regional pain syndrome type I. *International Journal of Pharmaceutical Sciences Review and Research*, 2012; 17 (1): 16-21.
19. Lakić, D., **Petrova G.**, Bogavac-Stanojević, N., Jelić-Ivanović, Z., Kos, M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model. *Biotechnology and Biotechnological Equipment*, 2012; 26 (3):3066-3072.
IF=0.622
20. Valov V, Palmer J, Czech M, Savova A, **Petrova G.** Cost-effectiveness of biphasic insulin aspart 30 vs. human premix insulin in type 2 diabetes from the payer's perspective in bulgaria. *Biotechnol Biotechnol Equip.* 2012;26(2):2937-44.
IF=0.622
21. Savova A, **Petrova G.** Gotseva A, Kurcatova A, Koguharova M. Economic analysis 20 years after the introduction of universal HBV immunisation in bulgaria. *Biotechnol Biotechnol Equip.* 2012;26(1): 2811-6.
IF=0.622
22. Peikova L, Manova M, Pencheva I, **Petrova G.** Chirality as a patent protection policy -

an example with citalopram. Biotechnol Biotechnol Equip. 2012;26(3):3058-61.

IF 0.622

2013

23. Bogavac-Stanojević N., Dopsaj V., Jelić-Ivanović Z, Lakić D., Vasić D., **Petrova G.** Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. Biochemia Medica 2013;23(1):96–106 <http://dx.doi.org/10.11613/BM.2013.012>
24. **Петрова Г.**, Етични аспекти на фармацевтичните научни изследвания. Сборник статии от 9-та нац. Конференция с межд. Участие на тема етика 2013; 178-181
25. Марчева М., Тошева Л., **Г. Петрова**, Модели на ценообразуване и реимбурсация на лекарства в страните от Централна и Източна Европа. Сборник статии от 9-та нац. Конференция с межд. Участие на тема етика 2013; 193-199
26. М. Димитрова, М. Донева и **Г. Петрова**. Изчисляване на бюджетното въздействие на лечението на имунодефицитни състояния със заместителна терапия с човешки, нормален имуноглобулин за подкожно приложение. Детски и инфекциозни болести, 2013; V (1№:38-43
27. Kamusheva, M., Stoimenova, A., Doneva, M., Zlatareva, A., **Petrova, G.** A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania. Biotechnology and Biotechnological Equipment, 2013;27 (5):4186-4192, DOI: 10.5504/BBEQ.2013.0066 **IF=0.622**
28. Petkova, E., Petkova, V., Konstantinova, M., **Petrova G.** Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children - economic evaluation. BMC Pediatrics, 2013;13 (1), art. no. 155, DOI: 10.1186/1471-2431-13-155 **IF=1.159**
29. Doneva, M., Valov, V., Borisova, A.-M., Tankova, T., Savova, A., Manova, M., Czech, M., **Petrova G.** Comparative analysis of the cost of insulin treated patients in Bulgaria. Biotechnology and Biotechnological Equipment, 2013; 27 (2):3748-3752. DOI: 10.5504/BBEQ.2013.0001 **IF=0.622**
30. Kamusheva MS, N Gerasimov, Guenka I Petrova. Intestinal gel Levodopa+ Carbidopa in Parkinson's patients with frequent and prolonged akinesia-an economic evaluation. Int J Pharm Sci Rev Res, 2013; 22 (1): 244-246
31. Dimitrova, M., **Petrova, G.**, Manova, M., Savova, A., Yancheva, N., Cervenjakova, T., Mitov, K., Stefanova, M. Economic impact of the highly active antiretroviral pharmacotherapy on cost and HIV/AIDS control in Bulgaria Biotechnology and Biotechnological Equipment, 2013; 27 (1): 3599-3604. DOI: 10.5504/bbeq.2012.0076 **IF=0.622**
32. **G Petrova**, N Mateev, D Barumov, L Peikova et al .Modeling the Customer Satisfaction

Influence on the Long Term Sales: Example with Leading OTC Analgesics INN on National Market. Modern Economy, 2013; 4: 567-595

33. Odalović M, D Lakić, I Tadić, L Tasić, **G Petrova**. How much do we pay for caesarean section: A pilot study in Serbia, Acta chirurgica iugoslavica, 2013; 60 (1): 47-51
34. Georgieva S, **Petrova G**, Dimitrova M, Peikova L., Paskalev E., Filipov J, Zlatkov B. Prospective Study of the Changes in pharmacotherapy. Cost of Adult Kidney Transplant Patients in Bulgaria. Modern Economy. 2013; 4 (12): article ID:40809,5 pages DOI:10.4236/me.2013.412089
35. Savova A, Kamusheva M, Georgieva S, Stoimenova A, **Petrova G**. Budget impact analysis of chronic myeloid leukemia treatment in bulgaria. Biotechnol Biotechnol Equip. 2013;27(1):3595-8. **IF=0.54**

2014

36. Inotai, A., **Petrova, G.**, Vitezic, D., Kaló, Z. Benefits of investment into modern medicines in Central-Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2014; 14 (1): 71-79. DOI: 10.1586/14737167.2014.868314 **IF=2.3**
37. Danko, D., **Petrova, G.** Health technology assessment in the Balkans: Opportunities for a balanced drug assessment system. Biotechnology and Biotechnological Equipment, 2014; 28 (6): 1181-1189. DOI: 10.1080/13102818.2014.978636 **IF=0.54**
- 38. Petrova, G.**, Tachkov, K., Georgieva, S., Dimitrova, M. Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: Prophylactic vs. on-demand treatment. Biotechnology and Biotechnological Equipment, 2014; 28 (3): 576-582. DOI: 10.1080/13102818.2014.926687 **IF=0.54**
39. Mitkova, Z., Manova, M., **Petrova, G**. Impact of the generic competition on reference prices of cardiovascular medicines. Pharmacia, 2014; 61 (3): 9-16.
40. Lakić, D., Petrović, B., **Petrova, G**. Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data. Srpski Arhiv za Celokupno Lekarstvo, 2014; 142 (11-12): 688-694.DOI: 10.2298/SARH1412688L **IF=0.2**
41. Valov, V., Doneva, M., Borisova, A.M., Tankova, T., Czech, M., Manova, M., Savova, A., Peikova, L., **Petrova, G**. Regional differences in diabetic patients' pharmacotherapy in Bulgaria. European Review for Medical and Pharmacological Sciences, 2014; 18 (10): 1499-1506. **IF=3.1**
42. Gulácsi, L., Rotar, A.M., Niewada, M., Löblövá, O., Rencz, F., **Petrova, G.**, Boncz, I., Klazinga, N.S. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. European Journal of Health Economics, 12014; 5 (Supp 1): S13-S25. DOI: 10.1007/s10198-014-0590-8 **IF=2.367**

43. Dimitrova M, **Petrova G**, Tachkov K, Bozhkova MK, Kamusheva M, Mitov K. Economic consequences of the vaccination against hepatitis A in the bulgarian healthcare setting. Biotechnol Biotechnol Equip. 2014;28(2):366-71.

IF=0.58

44. Benbassat BV, M Doneva, **GI Petrova** -Pharmacotherapy Cost of Controlled Ovarian Hyperstimulation of in Vitro Fertilization-A Real Life Study. Pharmacology & Pharmacy, 2014; 5 (10): 919-23

2015

45. Petrov, M., Dimitrova, M., **Petrova, G**. Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria. Value in Health Regional Issues, 2015; 7: 94-103. DOI: 10.1016/j.vhri.2015.09.004

IF=2.0

46. Dimitrova M, Doneva M, Valov V, Yordanova S, Manova M, Savova A, Mitov K, **Petrova G**, Petkova V, Czech M. Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria. Biotechnol Biotechnol Equip. 2015; 29(4):805-13.

IF=0.373

2016

47. Dimitrova, M., Tachkov, K., **Petrova, G**. Cost-effectiveness assessment of liver disease therapy in Bulgaria. Journal of the Balkan Tribological Association, 2016; 22 (4-II): 4146-4158.

IF=0.142

48. Boyadzhieva VL., N. Stoilov, R. Stoilov, **G. Petrova**. Cost of treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis with biological disease-modifying antirheumatic drugs in the period 2013-2014 in Bulgaria. Journal of the Balkan tribological association, 2016; 22 (1): 401-409 (IF 0.508)

IF=0.142

49. **Petrova, G**., Benbassat, B., Lakic, D., Dimitrova, M., Mitov, K., Dimitrov, J. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. Biotechnology and Biotechnological Equipment, 2016; 30 (3): 614-621. Cited 1 time. DOI: 10.1080/13102818.2016.1160796

IF=0.373

50. **Petrova G**, Doneva M, Mitkova Z, Tachkov K, Manova M. Generics and fixed-dose combinations in cardiology: Satisfaction analysis of pharmacists and cardiologists. Biotechnol Biotechnol Equip. 2016; 30(1): 204-11. (IF 0.373)

IF=0.373

51. Jakubczyk M, Lipka I, Pawęska J, Niewada M, Rdzanek E, Zaletel J, Ramírez de Arellano A, Doležal T, Chekhorova Mitreva B, Nagy B, **Petrova G**, Šarić T, Yfantopoulos J, Czech M. Cost of severe hypoglycaemia in nine european countries. J Med Econ 2016; 19 (10): 973-82.

IF=2.956

52. Mitkova Z, Vasileva M, Savova A, Manova M, **Petrova G**. Analysis of cardiovascular medicines prices and reimbursement in Bulgaria and Romania. Revista Farmacia. 2016;64(4):633-42.

IF=1.6

2017

53. Ferrario, A., Arāja, D., Bochenek, T., Čatić, T., Dankó, D., Dimitrova, M., Fürst, J., Greičiūtė-Kuprijanov, I., Hoxha, I., Jakupi, A., Laidmäe, E., Löblová, O., Mardare, I., Markovic-Pekovic, V., Meshkov, D., Novakovic, T., **Petrova, G.**, Pomorski, M., Tomek, D., Voncina, L., Haycox, A., Kanavos, P., Vella Bonanno, P., Godman, B. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. *PharmacoEconomics*, 2017; 35 (12): 1271-1285. DOI: 10.1007/s40273-017-0559-4 **IF=4.7**
54. Kawalec, P., Stawowczyk, E., Tesar, T., Skoupa, J., Turcu-Stiolica, A., Dimitrova, M., **Petrova G.I.**, Rugaja, Z., Männik, A., Harsanyi, A., Draganic, P. Pricing and reimbursement of biosimilars in central and Eastern European countries. *Frontiers in Pharmacology*, 2017; 8 : art. no. 288. DOI: 10.3389/fphar.2017.00288 **IF=5.988**
55. Benbassat, B., Mitov, K., Savova, A., Tachkov, K., **Petrova, G.** Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level. *Biotechnology and Biotechnological Equipment*, 2017; 31 (1): 206-214. DOI: 10.1080/13102818.2016.1261636 **IF=0.373**
56. Maria Dimitrova, Kaloyan Pavlov, Konstantin Mitov, Jordan Genov, **Guenka Ivanova Petrova**. Chronic hepatitis c-related cirrhosis hospitalization cost analysis in Bulgaria. *Frontiers in medicine* 2017; 4: 12 **IF=3.9**
57. Kamusheva M, Dimitrova M, van Boven JF, Postma MJ, van der Molen T, Kocks JW, Mitov K, Doneva M, Petrova D, Georgiev O, Petkova V, **Petrova G.** Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. *J Med Econ.* 2017;20(5):503-509. doi: 10.1080/13696998.2017.1279620. **IF=2.956**
58. Tachkov K., **G. Petrova**. Budget impact analysis of inhibitors hemophilia therapy with bypassing agents. *Journal of IMAB.* 2019; 25 (2): 2511-2515

2018

59. Manoela Manova, Alexandra Tzvetanova Savova, Mariya Andreeva Vasileva, Silvia , Maria Kamusheva, Daniela Grekova, Valentina Petkova, **Guenka Ivanova Petrova**. Comparative analysis of prices of biological products for treatemnt of rheumatoid arthritis. *Front Pharmacol.* 2018; 9: 1070. doi: 10.3389/fphar.2018.01070. **IF=5.988**
60. M. Kamusheva, M. Vasileva, A. Savova, M. Manova, **G. Petrova**. An overview of the reimbursement decision-making processes in Bulgaria as a reference country for the middle-income European countries. *Frontiers in Public Health*, 2018;6:61. **IF=3.9**
61. Grekova, D.D., Andreevska, K.G., **Petrova, G.**, Petkova, V. Assessment of the social and economic burden of glaucoma in Bulgaria. *Biomedical Research (India)*, 2018; 29 (12): 2578-2581. DOI: 10.4066/biomedicalresearch.29-18-647

62. Ignatova D, Onchev G, **Petrova G**, Kamusheva M. Burden of informal care for individuals with schizophrenia and affective disorders prior to hospital admission, The European Journal of Psychiatry, 2018, 12 (24): DOI: 10.1016/j.ejpsy.2018.11.002

IF=1.8

2019

63. Ignatova D, Kamusheva M, **Petrova G**, Onchev G, Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. Biotechnology & Biotechnological Equipment, 2019; 11(1): 1-10

IF=0.373

64. Tachkov K., Konstantin M., Kamusheva M., Doneva M., **Petrova G**. Pilot study on the cost of some oncohematology diseases in Bulgaria. Front. Public Health (Health economics). 2019; 7: 70. doi: 10.3389/fpubh.2019.00070

IF=3.9

65. Vassileva M, M Kamusheva, M Manova, A Savova, K Tachkov, **G Petrova**. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert Review of Pharmacoeconomics & Outcomes Research 2019; 11 (2) <https://doi.org/10.1080/14737167.2019.1592680>

IF=2.039

66. Kamusheva, M., Rusenova, Y., Vandeva, S., Elenkova, A., Zaharieva, S., Doneva, M., Mitkova, Z., **Petrova, G**. Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review, Biotechnology & Biotechnological Equipment. 2019;33:1, 1560-1571, DOI: 10.1080/13102818.2019.1680317

IF=0.373

67. Dimitrova, D., Tachkov, K., **Petrova, G**. Economic consequences of the implementation of national screening program for chronic HCV infection, Expert Review of Pharmacoeconomics & Outcomes Research, 2019, DOI:10.1080/14737167.2019.1666000

IF=2.039

68. Tachkov K., Mitov K., Mitkova Z., Kamusheva M., Dimitrova M., Petkova V., Savova A., Doneva M., Tcharukciev D., Valov V., Angelova G., Manova M., **Petrova G**. Improved quality of diabetes control reduces complication costs in Bulgaria Biotechnology & Biotechnological Equipment, 2019; 33 (1): 814-820, DOI: 10.1080/13102818.2019.1604160.

IF=1.4

69. Grelewska J, Jakubczyk M, Niewada M, Lipka I, **Petrova G**, Tcharaktchiev D, Mitkova Z, Tsonev S, Verkauskiene R, Pejicic S, Vulic D, Seranic A, Pana A, Vasile Ileanu B, Bonča P, Janša K, Valov V, Jokubauskiene G, Hałdaś M, Jusufovic R, Ciocirlan R, Stariha J, Russel-Szymczyk M. The cost of macro- and microvascular diseases in patients with diabetes mellitus in selected Central and Eastern European countries. DOI:10.7365/ Journal of health policy and outcomes research. 2019, 1:1-17

70. Mitkova, Z., Mitov, K., Valov, V., Manova, M., Savova, A., Kamusheva, M., Tcharaktchiev, D., Angelov, Z., Angelova, **Petrova, G**. Incretins and SGLT-2I therapy of type 2 diabetes – Real life study of their therapeutic and economic effects. Frontiers in Pharmacology, 2019; 10: art. no. 364, DOI: 10.3389/fphar.2019.00364

IF=5.988

71. Tkachova O, Iakovlieva L, Mitkova Z, Manova M, Savova A, **Petrova G**. An affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. BMC Health Services Research. 2019;19(1):902.. doi:10.1186/s12913-019-4736-3

IF=2.8

2020

72. Mitkova, Z., Vasileva, M., Savova, A., Manova, M., Terezova, S., **Petrova, G**. Comparison of Cardiovascular Medicines Prices in Four European Countries. Frontiers in Public Health (Health economics), 2020; 8, art. no. 433, DOI: 10.3389/fpubh.2020.00433

IF=3.8

73. Milushewa, P., Doneva, M., **Petrova, G**. Pharmacoeconomic studies of the asthma therapy. General Medicine, 2020; 22 (1): 57-66.

74. Tachkov K., D. Ignatova, K. Mitov a, M. Kamushevaa, G. Petrova. Trends in the cost and utilization of psychotropic medicines for major psychiatric disorders in Bulgaria from 2013 to 2017. Eur. J. Psychiat. 2021; 35 (1): 33-40, doi:10.1016/j.ejpsy.2020.09.001

IF=1.8

2021

75. Seitaridou Y, Tsekov I, Kamusheva M, Dimitrova M, **Petrova G**. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics & Outcomes Research. 2021; 22(2):241-246. doi: 10.1080/14737167.2021.1981134.

IF=2.039

76. Tachkov, K.; Mitkova, Z.; Boyadzieva, V.; **Petrova, G**. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. Pharmaceuticals 2021; 14: 64. <https://doi.org/10.3390/ph14010064>

IF=4.6

77. Mitkova, Z. **Petrova, G**. Analysis of the Household and HealthCare System Expenditures in Bulgaria. Frontiers in Public Health (Health economics) 2021; 9:675277. doi: 10.3389/fpubh.2021.675277

IF=3.8

78. Tachkov, K.; Mitkova, Z.; Milushewa, P.; **Petrova, G**. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. Healthcare 2021; 9: 697. <https://doi.org/10.3390/healthcare9060697>

IF=2.8

79. Mitkova, Z., **Petrova, G**. Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. Iranian Journal of Pharmaceutical Research, 2021; 20 (2): 403-416. DOI: 10.22037/ijpr.2020.113660.14418

IF=0.51

80. Tabor, B., Jakubczyk, M., Bojanic, L., Zawodnik, S., Bojkow, S., Chahoud, L., Sweeney, N., Benkovic, V., Christodoulou, C., Dimitrova, M., Liepina, E., Ondrušová, M., Pana, A., **Petrova, G**, Petrovica, M., Ulici, A., Niewada, M. The economic burden of advanced breast cancer. Journal of Health Policy and Outcomes Research, 2021; (2): 42-65. DOI: 10.7365/JHPOR.2021.2.6

81. Kostova, D., Stoev, S., Tachkov, K., **Petrova, G.** Cost-effectiveness of in vitro fertilization and controlled ovarian hyperstimulation before and after the COVID-19 outbreak. *Biotechnology and Biotechnological Equipment*, 2021; 35 (1):1821-1827. DOI: 10.1080/13102818.2021.2022993 **IF=1.4**

82. Godman, B., Hill, A., Simoens, S., Selke, G., Selke Krulichová, I., Zampirolli Dias, C., Martin, A.P., Oortwijn, W., Timoney, A., Gustafsson, L.L., Voncina, L., Kwon, H.-Y., Gulbinovic, J., Gotham, D., Wale, J., Cristina Da Silva, W., Bochenek, T., Allocati, E., Kurdi, A., Ogunleye, O.O., Meyer, J.C., Hoxha, I., Malaj, A., Hierländer, C., Sauermann, R., Hamelinck, W., **Petrova, G.**, Laius, O., Langner, I., Yfantopoulos, J., Joppi, R., Jakupi, A., Greiciute-Kuprijanov, I., Vella Bonanno, P., Piepenbrink, J., de Valk, V., Wladysiuk, M., Marković-Peković, V., Mardare, I., Fürst, J., Tomek, D., Obach Cortadellas, M., Zara, C., Pontes, C., McTaggart, S., Laba, T.-L., Melien, Ø., Wong-Rieger, D., Bae, S., Hill, R. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, 2021; 21 (4): 527-540. DOI: 10.1080/14737167.2021.1884546 **IF=2.039**

83. Kamusheva M, Turcu-Stiolica A, Gierczynski J, Subtirelu M-S, Czech M., **Petrova G.** Do Advanced Therapies Have a Future in the Low and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland. *Front. Public Health*, 2021; 9:729847. doi: 10.3389/fpubh.2021.729847 **IF=3.8**

84. Tachkov, K., Boydzhieva, V., Mitkova, Z., Stoilov, N., **Petrova, G.** Pharmacoeconomic models in rheumatology. *Rheumatology (Bulgaria)*, 2021; 29: 15-39. DOI: 10.35465/29.4.2021

85. Godman B., Haque M., Leong T., Allocati E., Kumar S., Islam S., Charan J., Akter F., Kurdi A., Vassalo C., Bakar M., Rahim S., Sultana N., Deeba F., Khan M., Muksudul A. B. M., Jahan I., Kamal Z., Hasin H., Murshid M., Nahar S., Haque M., Dutta S., Abhayanand J., Kaur R., Rwegerera G., Macedo do Nascimento R., Godói I., Irfan M., Amu A., Matowa P., Acolatse J., Inoom R., Sefah I., Acharya J., Opanga S., Njeri L., Kimonge D., Kwon H.-Y., Bae S., Khuan K., Abubakar A., Sani I., Khan T., Hussain S., Saleem Z., Malande O., Piloya-Were T., Gambogi R., Ortiz C., Alutuli L., Kalungia A., Hoxha I., Markovic-Pekovic V., Tubic B., **Petrova G.**, Tachkov K., Laius O., Harsanyi A., Inotai A., Jakupi A., Henkuzens S., Garuoliene K., Gulbinovic J., Wladysiuk M., Rutkowski J., Mardare I., Fürst J., McTaggart S., MacBride-Stewart S., Pontes C., Zara C., Tagoe E., Banzi R., Wale J. and Jakovljevic M.. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. *Front. Public Health (Sec. Health Economics)* 2021; 9, <https://doi.org/10.3389/fpubh.2021.671961> **IF=3.8**

86. Daubner-Bendes R, Kovács S, Niewada M, Huic M, Drummond M, Ciani O, Blankart CR, Mandrik O, Torbica A, Yfantopoulos J, **Petrova G.**, Holownia-Voloskova M, Taylor RS, Al M, Piniashko O, Lorenzovici L, Tarricone R, Zemplényi A and Kaló Z. Quo Vadis HTA for

Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Front. Public Health* (Section health economics) 2021;8:612410. doi: 10.3389/fpubh.2020.612410 **IF=3.8**

2022

87. Tachkov K, Boyadzhieva V, Manev I, Stoilov N, Mitkova Z, Mitov K, **Petrova G**. Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level, *Biotechnology & Biotechnological Equipment*, 2022; 36:1: 828-837, DOI: 10.1080/13102818.2022.2131468

IF=1.4

88. Mitkova, Z., Dimitrova, M., Doneva, M., Tachkov, K., Kamusheva, M., Marinov, L., Gerasimov, N., Tcharaktchiev, D., **Petrova, G**. Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria. *Frontiers in Public Health* (Health economics), 2022; 10: 1011928, DOI: 10.3389/fpubh.2022.1011928

IF=5.8

89. Mitkova, Z., Doneva, M., Gerasimov, N., Tachkov, K., Dimitrova, M., Kamusheva, M., **Petrova, G**. Analysis of Healthcare Expenditures in Bulgaria. *Healthcare* (Switzerland), 2022; 10 (2): art. no. 274, DOI: 10.3390/healthcare10020274

IF=2.8

90. Tachkov, K., Zemlenyi, A., Kamusheva, M., Dimitrova, M., Siirtola, P., Pontén, J., Nemeth, B., Kalo, Z., **Petrova, G**. Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries. *Frontiers in Public Health*, 2022; 10, art. no. 921226, DOI: 10.3389/fpubh.2022.921226

IF=5.8

91. Kirilova-Doneva, M., Kamusheva, M., Gerasimov, N., **Petrova, G**. Cost-Utility Analysis of Open Hernia Operations in Bulgaria. *Acta Medica Bulgarica*, 2022; 49(2): 22–27

92. Pisana A., Wettermark B., Kurdi A., Tubic B., Pontes C., Zara C., Van Ganse E., **Petrova G**, Mardare I., Fürst J., Roig-Izquierdo M., Melien O., Vella Bonanno P., Banzi R., Marković-Peković V., Mitkova Z., Godman B. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries *Front. Pharmacol.*, 2022; (13) Sec. Drugs Outcomes Research and Policies <https://doi.org/10.3389/fphar.2022.873556>

IF=5.988

93. Mitkova Z., Dimitrova M., Mitkov J., **Petrova G**. Impact of COVID-19 pandemic on outpatient depression treatment and NHIF expenditure. *Journal of Applied Pharmaceutical Science*, 2021; 12(05): 142-148, DOI: 10.7324/JAPS.2022.120511

2023

94. Manova M, Mitkova ZE, Savova A, Borisova A, Peikova L, Mitkov J, **Petrova G**. Impact of generics competition on prices and utilization of antiepileptic medicines in Bulgaria. *Journal of Applied Pharmaceutical Science*, 2023. <https://doi.org/10.7324/JAPS.2023.115004>

95. Tachkov, K., Savova, A., Manova, M., **Petrova, G.** Tackling reimbursement challenges to fair access to medicines—introduction to the topic. *Expert Review of Pharmacoeconomics and Outcomes Research*, 2023; 23 (6): 597-606. DOI: 10.1080/14737167.2023.2203384 **IF=2.039**

96. Zemplényi, A., Tachkov, K., Balkanyi, L., Németh, B., Petykó, Z.I., **Petrova, G.**, Czech, M., Dawoud, D., Goettsch, W., Gutierrez Ibarluzea, I., Hren, R., Knies, S., Lorenzovici, L., Maravic, Z., Piniazhko, O., Savova, A., Manova, M., Tesar, T., Zerovnik, S., Kaló, Z. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment. *Frontiers in Public Health*, 2023; 11, art. no. 1088121, DOI: 10.3389/fpubh.2023.1088121 **IF=5.2**

97. Tachkov K., Nikolova P., Vitanska-Simeonova R., Boyadzhieva V., Stoilov N., **Petrova G.**, Cost-effectiveness of therapeutic drug monitoring (TDM) of biologic treatment in rheumatic diseases: a narrative review, *Biotechnology & Biotechnological Equipment*, 2023, 37, 1, <https://doi.org/10.1080/13102818.2023.2250469> **IF=1.4**

98. Mitkova Z., Manev I., Tachkov K., Boyadzhieva V., Stoilov N., Doneva M., **Petrova G.** How Managed Entry Agreements Influence the Patients Affordability to Biological Medicines—Bulgarian Example. *Healthcare* 2023; 11: 2427. <https://doi.org/10.3390/healthcare11172427> **IF=2.8**

99. Savova A., Manova M., Tachkov K., **Petrova G.** The role of insurance policies in the drug pricing landscape, *Expert Review of Pharmacoeconomics & Outcomes Research*, 2023; DOI: 10.1080/14737167.2023.2292693 **IF=2.039**

100. Dimitrova M., Seitaridou Y., Lazarova R., **Petrova G.**, Mitov K., Milanov I., Marinov L., Kamusheva M., Panayotov P. Cost-effectiveness of disease-modifying treatments for multiple sclerosis in Bulgaria based on evidence from real world settings. *FARMACIA*, 2023, Vol. 71, 6: 1324-1331, <https://doi.org/10.31925/farmacia.2023.6.24> **IF=1.1**

101. Dimitrova M., Dimitrov R., Ahchiyska K., Nikolaeva M., Ganova M., **Petrova G.** Digital health in Bulgaria: Imagination or possible reality? *Pharmacia* 2023; 70(3): 649–655 DOI 10.3897/pharmacia.70.e108957 **IF=1.1**

102. Karanyotova S, Topova B, Petrova E, Doychev P, Kapitanska E, **Petrova G**, Mitkova Z and Dimitrova M. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria. *Front. Public Health* 2023; 11:1073733. doi: 10.3389/fpubh.2023.1073733 **IF=6.462**

2024

103. Dadanbekova D., Zhakipbekov K., Kodasbayev A., Datkhayev U., **Petrova G.**, Tachkov K. Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan. *Pharmacia*, 2024; 70(3): 649–655 DOI 10.3897/pharmacia.70.e108957 **IF=1.1**
104. Jakubowski S, Kawalec P, Holko P, Kowalska-Bobko I, Kamusheva M, **Petrova G.**, Draganić P, Fuksa L, Männik A, Ispán F, Briedis V, Bianchi I, Paveliu MS, Tesar T. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries. *Front. Pharmacol.* 2024; 15:1369178. doi: 10.3389/fphar.2024.1369178 **IF=5.6**
105. Dimitrova M., Petrov M., **Petrova G.**, Mitkova Z. Economic consequences of the implementation of primary DNA-HPV genotype testing in Bulgaria, *Biotechnology & Biotechnological Equipment*, 2024; 38:1, 2358134, DOI:10.1080/13102818.2024.2358134 **IF=1.4**